Approval · Notice of Compliance 4839 · 2004
AVALIDE: Notice of Compliance 4839
Issued August 13, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4839
- Date
- August 13, 2004
- Company
- Sanofi-Synthelabo Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New formulation: reduced mass/film coated tablet
- Therapeutic class
- Angiotensin ii at1 receptor blocker, diuretic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVALIDE | Not yet assigned | — |
Medicinal ingredients
- IRBESARTAN 150 MG per TAB
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- IRBESARTAN 300 MG per TAB